Unraveling the Puzzle of High Drug Prices in the United States: A Systemic Analysis and Policy Implications of March-In Rights

The United States, often perceived as a global beacon of power and prosperity, grapples with a paradoxical reality concerning its healthcare system and drug prices. Despite its stature, the nation’s healthcare landscape is marred by exorbitant pharmaceutical costs, raising concerns among policymakers and families alike. This paper delves into the complex web of factors contributing to the abundance of high drug prices in the United States, shedding light on the role of pharmaceutical companies and the dynamics of patent protection, and analysis the newly released March-in Rights framework created by the Biden-Harris Administration. But is the framework enough to truly lower drug prices? Unlikely.